文献速递生殖医学

第二剂kisspeptin-54改善卵巢过度刺激综合征高风险女性的卵母细胞成熟:一项2期随机对照试验

A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial.
PubMed 文献 · Hum Reprod · 2017-01-01

这项2期随机安慰剂对照试验纳入62例OHSS高风险女性,在首次kisspeptin-54触发后10小时追加第二剂,评估卵母细胞成熟率。结果显示双剂组卵母细胞获取率≥60%的比例为71%,单剂组为45%,绝对差异+26%(CI 2-50%,P=0.042),且未增加卵巢过度反应和中度OHSS的发生。

要点

  • OHSS高风险女性首次kisspeptin-54触发后10小时追加第二剂可提高卵母细胞获取率。
  • 双剂组卵母细胞获取率≥60%的比例为71%,单剂组为45%,绝对差异+26%(CI 2-50%,P=0.042)。
  • 第二剂kisspeptin-54未增加卵巢过度反应和中度OHSS的发生频率。

核心结论

  • 在OHSS高风险女性中,首次kisspeptin-54触发后10小时追加第二剂可改善卵母细胞获取。

研究设计与样本

  • 2期随机安慰剂对照试验,2015年8月至2016年5月招募62例OHSS高风险女性,随机1:1接受第二剂kisspeptin-54(双剂组,n=31)或生理盐水(单剂组,n=31)。
  • 所有患者(n=62)在取卵前36小时皮下注射kisspeptin-54(9.6 nmol/kg),10小时后给予第二剂或安慰剂。
  • 研究在伦敦Hammersmith Hospital IVF unit单中心进行;患者、胚胎学家和IVF临床医生对分组设盲。

主要发现

  • 双剂组卵母细胞获取率≥60%的比例为71%(21/31),单剂组为45%(14/31),绝对差异+26%(CI 2-50%,P=0.042)。
  • 第二剂kisspeptin-54在给药后4小时诱导进一步LH分泌;LH反应因首次kisspeptin注射后的LH反应而异。
  • 首次kisspeptin后LH升高较低的患者,第二剂后出现更明显的「挽救」LH反应。
  • 卵巢过度反应和中度OHSS发生频率:单剂组1/31(3.2%),双剂组0/31(0%)。

关键数值与推荐

  • OHSS高风险定义:窦卵泡计数≥23或抗苗勒管激素水平≥40 pmol/L。
  • 主要结局:卵母细胞获取率(从首次kisspeptin-54触发当日早晨直径≥14 mm的卵泡中获取的成熟卵母细胞百分比)至少达到60%的患者比例。
  • 次要结局:生殖激素水平、着床率和OHSS发生情况。

临床怎么用

  • 作者认为,kisspeptin触发最终卵母细胞成熟是一种新颖的治疗选择,可使OHSS高风险女性仍能进行新鲜胚胎移植。

局限性

  • 需要进一步研究直接比较kisspeptin-54与更成熟的卵母细胞成熟触发方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can increasing the duration of LH-exposure with a second dose of kisspeptin-54 improve oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS)? SUMMARY ANSWER: A second dose of kisspeptin-54 at 10 h following the first improves oocyte yield in women at high risk of OHSS. WHAT IS KNOWN ALREADY: Kisspeptin acts at the hypothalamus to stimulate the release of an endogenous pool of GnRH from the hypothalamus. We have previously reported that a single dose of kisspeptin-54 results in an LH-surge of ~12-14 h duration, which safely triggers oocyte maturation in women at high risk of OHSS. STUDY DESIGN, SIZE, DURATION: Phase-2 randomized placebo-controlled trial of 62 women at high risk of OHSS recruited between August 2015 and May 2016. Following controlled ovarian stimulation, all patients (n = 62) received a subcutaneous injection of kisspeptin-54 (9.6 nmol/kg) 36 h prior to oocyte retrieval. Patients were randomized 1:1 to receive either a second dose of kisspeptin-54 (D; Double, n = 31), or saline (S; Single, n = 31) 10 h thereafter. Patients, embryologists, and IVF clinicians remained blinded to the dosing allocation. PARTICIPANTS/MATERIALS, SETTING, METHODS: Study participants: Sixty-two women aged 18-34 years at high risk of OHSS (antral follicle count ≥23 or anti-Mullerian hormone level ≥40 pmol/L). Setting: Single centre study carried out at Hammersmith Hospital IVF unit, London, UK. Primary outcome: Proportion of patients achieving an oocyte yield (percentage of mature oocytes retrieved from follicles ≥14 mm on morning of first kisspeptin-54 trigger administration) of at least 60%. Secondary outcomes: Reproductive hormone levels, implantation rate and OHSS occurrence. MAIN RESULTS AND THE ROLE OF CHANCE: A second dose of kisspeptin-54 at 10 h following the first induced further LH-secretion at 4 h after administration. A higher proportion of patients achieved an oocyte yield ≥60% following a second dose of kisspeptin-54 (Single: 14/31, 45%, Double: 21/31, 71%; absolute difference +26%, CI 2-50%, P = 0.042). Patients receiving two doses of kisspeptin-54 had a variable LH-response following the second kisspeptin dose, which appeared to be dependent on the LH-response following the first kisspeptin injection. Patients who had a lower LH-rise following the first dose of kisspeptin had a more substantial 'rescue' LH-response following the second dose of kisspeptin. The variable LH-response following the second dose of kisspeptin resulted in a greater proportion of patients achieving an oocyte yield ≥60%, but without also increasing the frequency of ovarian over-response and moderate OHSS (Single: 1/31, 3.2%, Double: 0/31, 0%). LIMITATIONS, REASONS FOR CAUTION: Further studies are warranted to directly compare kisspeptin-54 to more established triggers of oocyte maturation. WIDER IMPLICATIONS OF THE FINDINGS: Triggering final oocyte maturation with kisspeptin is a novel therapeutic option to enable the use of fresh embryo transfer even in the woman at high risk of OHSS. STUDY FUNDING/COMPETING INTEREST(S): The study was designed, conducted, analysed and reported entirely by the authors. The Medical Research Council (MRC), Wellcome Trust & National Institute of Health Research (NIHR) provided research funding to carry out the studies. There are no competing interests to declare. TRIAL REGISTRATION NUMBER: Clinicaltrial.gov identifier NCT01667406. TRIAL REGISTRATION DATE: 8 August 2012. DATE OF FIRST PATIENT'S ENROLMENT: 10 August 2015.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Abbara A, Clarke S, Islam R, et al. A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial. Hum Reprod. 2017. PMID: 28854728. doi:10.1093/humrep/dex253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。